GLP-1 Weight Loss Drugs Linked to Higher Scarring Risk After Tummy Tuck Surgery | Research

The takeaway

GLP-1 receptor agonist use independently increased hypertrophic scarring risk by 79% after abdominoplasty, and when combined with prior bariatric surgery, nearly doubled the risk of wound dehiscence.

79% increased scarring risk with GLP-1RAs
GLP-1 receptor agonist use was independently associated with a 79% increase in hypertrophic scarring after abdominoplasty — a finding confirmed in sensitivity analysis with a 140% increase compared to DPP-4 inhibitor users.

What the researchers found

In propensity score-matched analyses of abdominoplasty patients:

- GLP-1RA use independently increased hypertrophic scarring risk (RR=1.79, 95% CI 1.37-2.35), confirmed in sensitivity analysis against DPP-4 inhibitors (RR=2.40)

- Prior bariatric surgery increased hematoma risk (RR=1.55, 95% CI 1.11-2.17) and seroma risk (RR=1.55, 95% CI 1.19-2.02), but lowered hypertrophic scarring (RR=0.74) and systemic infections (RR=0.78)

- Combined BS + GLP-1RA use increased wound dehiscence risk (RR=1.92, 95% CI 1.12-3.38) and constitutional symptoms (RR=1.69, 95% CI 1.16-2.46)

The scarring finding with GLP-1RAs was robust across multiple analyses.

Why it matters

With millions of people now using GLP-1 receptor agonists for weight loss, and body contouring surgery demand surging, surgeons need to understand how these drugs affect surgical outcomes. The finding that GLP-1RAs significantly increase scarring risk — and that combining them with bariatric surgery worsens wound healing — has immediate implications for preoperative planning, patient counseling, and potentially the timing of drug discontinuation before surgery.

How the study worked

Retrospective cohort study using the TriNetX federated research network, including adults undergoing abdominoplasty from January 2004 to June 2025. Patients were categorized into four groups: no prior weight loss interventions, bariatric surgery only, recent GLP-1RA use only, and both. Propensity score matching controlled for confounders. Primary outcomes were 90-day postoperative complications. A sensitivity analysis compared GLP-1RA users to DPP-4 inhibitor users to isolate the GLP-1RA effect.

What this study cannot tell us

This is a retrospective observational study, so it cannot establish causation. The TriNetX network may have coding biases affecting how complications are recorded. The mechanism by which GLP-1RAs increase scarring is unknown and may involve direct tissue effects, nutritional status changes, or other factors. The study could not determine whether discontinuing GLP-1RAs before surgery would mitigate risks. Specific GLP-1RA drugs and doses were not differentiated.

How to read the evidence

This is a large retrospective cohort study with propensity score matching and sensitivity analyses, providing reasonably strong observational evidence. However, the retrospective design limits causal inference, and the mechanism behind the association is unknown.

When this study was published

Published in 2025 with data through June 2025, this is among the first large studies examining GLP-1RA effects on surgical outcomes — a critical topic as these drugs become widely used.

The bigger picture

This study addresses a rapidly emerging clinical question as GLP-1 drugs reshape the weight loss landscape. The intersection of pharmacological weight loss and cosmetic/reconstructive surgery is a new frontier in medicine. GLP-1 drugs' effects on wound healing, scarring, and tissue repair are not well understood, and this study provides the first large-scale data on their surgical complication profile — information that plastic surgeons, bariatric surgeons, and prescribing physicians all need.

Questions still open

What is the biological mechanism by which GLP-1 receptor agonists increase hypertrophic scarring risk?
Should GLP-1RA use be discontinued before body contouring surgery, and if so, how far in advance?
Do different GLP-1RA drugs (semaglutide vs. liraglutide vs. tirzepatide) carry different surgical risk profiles?

Common questions

Should I stop GLP-1 drugs before having a tummy tuck?

This study found that GLP-1 receptor agonist users had significantly higher scarring risk after abdominoplasty, and those who also had bariatric surgery faced increased wound healing problems. While the study cannot confirm whether stopping the drugs before surgery would reduce these risks, patients should discuss their GLP-1RA use with their surgeon as part of preoperative planning.

Why might GLP-1 drugs affect surgical healing?

The exact mechanism is not yet understood. GLP-1 receptor agonists affect many body systems beyond blood sugar — including inflammation, cell growth, and tissue repair processes. They also cause weight loss and can affect nutritional status, which may impact wound healing. More research is needed to determine the specific pathways involved.

Read the original research

Abdominoplasty After Bariatric Surgery and GLP-1 Receptor Agonists: Independent vs Combined Complication Risks.

Aesthetic surgery journal

View on PubMed ↗Publisher’s paper ↗

Citation

Boukind, Adam; He, Kevin; Speller, Nicholas; Badran, Saif. (2025). Abdominoplasty After Bariatric Surgery and GLP-1 Receptor Agonists: Independent vs Combined Complication Risks.. Aesthetic surgery journal. https://doi.org/10.1093/asj/sjaf244